CRISPR Therapeutics AG
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. CRISPR Therapeutics AG's past years’ income statements indicate that its last revenue has increased compared to the previous period by 85039% to $371,206,000. The net income raised on -$153,610,000 and profit margin reached -41%. Total operating expenses were $463,494,000.

Profit Margin

CRISPR Therapeutics AG (NASDAQ:CRSP): Profit margin
2014 0 -6.8M
2015 247K -25.82M -10456.68%
2016 5.16M -23.20M -449.3%
2017 40.99M -68.35M -166.74%
2018 3.12M -164.98M -5281.08%
2019 289.59M 66.85M 23.09%
2020 543K -348.86M -64247.7%
2021 913.08M 377.66M 41.36%
2022 436K -650.17M -149122.71%
2023 371.20M -153.61M -41.38%

CRSP Income Statement (2014 – 2023)

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue
Revenue
371.20M436K913.08M543K289.59M3.12M40.99M5.16M247K0
Cost of revenue
130.25M110.25M17.95M269.40M179.36M069.8M012.57M1.51M
Gross profit
240.95M-109.81M895.12M-268.86M110.22M3.12M-28.80M5.16M-12.32M-1.51M
Operating exp.
Research and development
387.33M461.64M438.63M266.94M179.36M113.77M69.8M42.23M12.57M1.51M
Selling and marketing
0000000000
Total operating expenses
463.49M563.34M539.55M354.97M242.85M162.06M105.64M73.29M25.97M6.62M
Operating income
-222.53M-673.16M373.52M-354.43M46.74M-158.94M-64.64M-68.13M-25.72M-6.62M
Other income (expenses), net
71.81M22.66M6.00M6.37M20.56M-5.48M-1.96M53.46M-92K-236K
Income before tax
-150.72M-650.5M379.53M-348.05M67.30M-164.42M-66.60M-22.71M-25.82M-6.86M
Income tax expense
2.88M-325K1.87M809K448K553K1.74M484K7K-63K
Net income
-153.61M-650.17M377.66M-348.86M66.85M-164.98M-68.35M-23.20M-25.82M-6.8M
Earnings per share
Basic EPS
-1.94-8.364.97-5.291.23-3.44-1.71-1.89-0.88-0.23
Diluted EPS
-1.94-8.364.7-5.291.17-3.44-1.71-1.89-0.88-0.23
Data sourceData sourceData sourceData sourceData sourceData sourceData sourceData source